Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2005 Oct 19;2005(4):CD003566.
doi: 10.1002/14651858.CD003566.pub2.

Cardioselective beta-blockers for chronic obstructive pulmonary disease

S Salpeter  1 , T Ormiston, E Salpeter
Affiliations
Meta-Analysis

Cardioselective beta-blockers for chronic obstructive pulmonary disease

S Salpeter et al. Cochrane Database Syst Rev. .

Abstract

Background: Beta-blocker therapy has a proven mortality benefit in patients with hypertension, heart failure and coronary artery disease, as well as during the perioperative period. These drugs have traditionally been considered contraindicated in patients with chronic obstructive pulmonary disease (COPD).

Objectives: To assess the effect of cardioselective beta-blockers on respiratory function of patients with COPD.

Search strategy: A comprehensive search of the Cochrane Airways Group Specialised Register (derived from systematic searches of CENTRAL, MEDLINE, EMBASE and CINAHL) was carried out to identify randomised blinded controlled trials from 1966 to May 2005. We did not exclude trials on the basis of language.

Selection criteria: Randomised, blinded, controlled trials of single dose or longer duration that studied the effects of cardioselective beta-blockers on the forced expiratory volume in 1 second (FEV1) or symptoms in patients with COPD.

Data collection and analysis: Two independent reviewers extracted data from the selected articles, reconciling differences by consensus. Two interventions studied were the administration of beta-blocker, given either as a single dose or for longer duration, and the use of beta2-agonist given after the study drug.

Main results: Eleven studies of single-dose treatment and 9 of treatment for longer durations, ranging from 2 days to 12 weeks, met selection criteria. Cardioselective beta-blockers, given as a single dose or for longer duration, produced no change in FEV1 or respiratory symptoms compared to placebo, and did not affect the FEV1 treatment response to beta2-agonists. A subgroup analysis revealed no change in results for those participants with severe chronic airways obstruction or for those with a reversible obstructive component.

Authors' conclusions: Cardioselective beta-blockers, given to patients with COPD in the identified studies did not produce adverse respiratory effects. Given their demonstrated benefit in conditions such as heart failure, coronary artery disease and hypertension, cardioselective beta-blockers should not be routinely withheld from patients with COPD.

PubMed Disclaimer

Conflict of interest statement

None

Figures

1.1
1.1. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 1 Single‐dose FEV1 treatment effect (Treatment minus Placebo, % change from baseline).
1.2
1.2. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 2 Single‐dose respiratory symptoms (Participants with symptoms, Treatment minus Placebo).
1.3
1.3. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 3 Longer duration FEV1 treatment effect (Treatment minus Placebo, % change from baseline).
1.4
1.4. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 4 Longer duration respiratory symptoms (Participants with symptoms, Treatment minus Placebo).
1.5
1.5. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 5 SUBGROUP: Severe COPD, Single‐dose FEV1 treatment effect (Treatment minus Placebo, % change).
1.6
1.6. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 6 SUBGROUP: Severe COPD, Longer duration FEV1 treatment effect (Treatment minus Placebo, % change).
1.7
1.7. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 7 SUBGROUP: Reversible airway disease, Single‐dose FEV1 treatment effect (Treatment minus Placebo, % change).
1.8
1.8. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 8 SUBGROUP: Reversible airway disease, Longer duration FEV1 treatment effect (Treatment minus Placebo, % change).
1.9
1.9. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 9 SUBGROUP: Cardiovascular conditions, Single‐dose FEV1 treatment effect (Treatment minus Placebo, % change).
1.10
1.10. Analysis
Comparison 1 Beta‐blocker vs Placebo, Outcome 10 SUBGROUP: Cardiovascular disease, Longer duration FEV1 treatment effect (Treatment minus Placebo, % change).
2.1
2.1. Analysis
Comparison 2 Beta‐blocker + agonist vs Placebo + agonist, Outcome 1 Single‐dose Beta‐agonist treatment effect (Treatment‐agonist effect minus Placebo‐agonist effect, % change).
2.2
2.2. Analysis
Comparison 2 Beta‐blocker + agonist vs Placebo + agonist, Outcome 2 Longer duration Beta‐agonist treatment effect (Treatment‐agonist effect minus Placebo‐agonist effect,% change).
See this image and copyright information in PMC

Update of

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Adam 1982 {published data only}
    1. Adam WR, Meagher EJ, Barter CE. Labetalol, beta blockers, and acute deterioration of chronic airway obstruction. Clinical and experimental hypertension. Part A, Theory and Practice 1982;4(8):1419‐28. - PubMed
Anderson 1980 {published data only}
    1. Anderson G, Jariwalla AG, Al‐Zaibak M. A comparison of oral metoprolol and propranolol in patients with chronic bronchitis. The Journal of International Medical Research 1980;8(2):136‐8. - PubMed
Beil 1977 {published data only}
    1. Beil M, Ulmer WT. Effects of a new cardioselective beta‐adrenergic blocker (atenolol) on airway resistance in chronic obstructive disease [Wirkung eines neuen kardioselektiven Betablockers (Atenolol) auf den Stromungswiderstand bei chronisch obstruktiven Atemwegserkrankungen]. Arzneimittel‐Forschung 1977;27(1):419‐22. - PubMed
Butland 1983 {published data only}
    1. Butland RJ, Pang JA, Geddes DM. Effect of beta‐adrenergic blockade on hyperventilation and exercise tolerance in emphysema. Journal of Applied Physiology 1983;54(5):1368‐73. - PubMed
Chang 2010 {published data only}
    1. Change CL, Mills GD, McLachlan JD, Karalus NC, Hancox RJ. Cardio‐selective and non‐selective beta‐blockers in chronic obstructive pulmonary disease: effects on bronchodilator response and exercise. Internal Medicine Journal 2010;40:193‐200. - PubMed
Dorow 1986a {published data only}
    1. Dorow P, Clauzel AM, Capone P, Mayol R, Mathieu M. A comparison of celiprolol and chlorthalidone in hypertensive patients with reversible bronchial obstruction. Journal of Cardiovascular Pharmacology 1986;8(Suppl 4):S102‐S4. - PubMed
Dorow 1986b {published data only}
    1. Dorow P, Bethge H, Tonnesmann U. Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. European Journal of Clinical Pharmacology 1986;31(2):143‐7. - PubMed
Fenster 1983 {published data only}
    1. Fenster PE, Hasan FM, Abraham T, Woolfenden J. Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease. Clinical Cardiology 1983;6(3):125‐9. - PubMed
Fogari 1990 {published data only}
    1. Fogari R, Zoppi A, Tettamanti F, Poletti L, Rizzardi G, Fiocchi G. Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovascular Drugs and Therapy 1990;4(4):1145‐9. - PubMed
Hawkins 2009 {published data only}
    1. Hawkins NM, MacDonald MR, Petrie MC, Chalmers GW, Carter R, Dunn FG, McMurray JJV. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. European Journal of Heart Failure 2009;11:684‐690. - PubMed
Lammers 1985a {published data only}
    1. Lammers JW, Folgerin HT, Herwaarden CL. Ventilatory effects of long‐term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. British Journal of Clinical Pharmacology 1985;20(3):205‐10. - PMC - PubMed
Macquin‐Mavier 1988 {published data only}
    1. Macquin‐Mavier I, Roudot‐Thoraval F, Clerici C, George C, Harf A. Comparative effects of bisoprolol and acebutolol in smokers with airway obstruction. British Journal of Clinical Pharmacology 1988;26(3):279‐84. - PMC - PubMed
McGavin 1978 {published data only}
    1. McGavin CR, Williams IP. The effects of oral propranolol and metoprolol on lung function and exercise performance in chronic airways obstruction. British Journal of Diseases of the Chest 1978;72:327‐32. - PubMed
Perks 1978 {published data only}
    1. Perks WH, Chatterjee SS, Croxson RS, Cruilshank JM. Comparison of atenolol and oxprenolol in patients with angina or hypertension and co‐existent chronic airways obstruction. British Journal of Clinical Pharmacology 1978;5:101‐6. - PMC - PubMed
Ranchod 1982 {published data only}
    1. Ranchod A, Keeton GR, Benatar SR. The effect of beta‐blockers on ventilatory function in chronic bronchitis. South African Medical Journal 1982;61(12):423‐4. - PubMed
Schanning 1976 {published data only}
    1. Schanning J, Vilsvik JS. Beta1‐blocker (Practolol) and exercise in patients with chronic obstructive lung disease. Acta Medica Scandinavica 1976;199:61‐4. - PubMed
Sinclair 1979 {published data only}
    1. Sinclair DJ. Comparison of effects of propranolol and metoprolol on airways obstruction in chronic bronchitis. British Medical Journal 1979;1(6157):168. - PMC - PubMed
Sorbini 1982 {published data only}
    1. Sorbini CA, Grassi V, Tantucci C, Todisco T, Motolese M, Verdecchia P. Acute effects of oral metoptolol on ventilatory function in patients with chronic obstructive lung disease. Acta Therapeutica 1982;8:5‐16.
Tivenius 1976 {published data only}
    1. Tivenius L. Effects of multiple doses of metoprolol and propranolol on ventilatory function in patients with chronic obstructive lung disease. Scandinavian Journal of Respiratory Diseases 1976;57(4):190‐6. - PubMed
van der Woude 2005 {published data only}
    1. Woude HJ, Zaagsma J, Postmas DS, Winter TH, Julst M, Aalbers R. Detrimental effects of beta‐blockers in COPD. A concern for nonselective beta‐blockers. Chest 2005;127(3):818‐24. - PubMed
von Wichert 1982 {published data only}
    1. Wichert P. Reversibility of bronchospasm in airway obstruction. American Heart Journal 1982;104:446‐50. - PubMed
Wunderlich 1980 {published data only}
    1. Wunderlich J, Macha HN, Wudicke H, Huckauf H. Beta‐adrenoceptor blockers and terbutaline in patients with chronic obstructive lung disease. Effects and interaction after oral administration. Chest 1980;78(5):714‐20. - PubMed

References to studies excluded from this review

Abraham 1981 {published data only}
    1. Abraham TA, Hasan FM, Fenster PE, Marcus FI. Effect of intravenous metoprolol on reversible obstructive airways disease. Clinical Pharmacology and Therapeutics 1981;29(5):582‐7. - PubMed
Addis 1976 {published data only}
    1. Addis GJ, Thorp JM. Effects of oxprenolol on the airways of normal and bronchitic subjects. European Journal of Clinical Pharmacology 1976;9:259‐63. - PubMed
Anavekar 1982 {published data only}
    1. Anavekar SN, Barter C, Adam WR, Doyle AE. A double‐blind comparison of verapamil and labetalol in hypertensive patients with coexisting chronic obstructive airways disease. Journal of Cardiovascular Pharmacology 1982;4(Suppl):S374‐7. - PubMed
Camsari 2003 {published data only}
    1. Camsari A, Arikan S, Avan C, Kaya D, Pekdemir H, Cicek D, Kiykim A, Sezer K, Akkus N, Alkan M, Aydogu S. Metoprolol, a beta‐1 selective blocker, can be used safely in corornary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003;18:188‐192. - PubMed
Chester 1981 {published data only}
    1. Chester EH, Schwartz HJ, Fleming GM. Adverse effect of propranolol on airway function in nonasthmatic chronic obstructive lung disease. Chest 1981;79:540‐4. - PubMed
Clague 1984 {published data only}
    1. Clague HW, Ahmad D, Carruthers SG. Influence of cardioselectivity and respiratory disease on pulmonary responsiveness to beta‐blockade. European Journal of Clinical Pharmacology 1984;27(5):517‐23. - PubMed
Dal Negro 1981 {published data only}
    1. Dal Negro R, Turco R. Changes in alveolar ventilation distribution due to beta antagonists induced by four different drugs in patients with chronic obstructive lung disease. International Journal of Clinical Pharmacology, Therapy and Toxicology 1981;19:234‐5.
Dal Negro 1986 {published data only}
    1. Dal Negro RW, Zoccatelli O, Pomari C, Trevisan F, Turco P. Respiratory effects of four adrenergic blocking agents combined with a diuretic in treating hypertension with concurrent chronic obstructive lung disease. International Journal of Clinical Pharmacology Research 1986;6(4):283‐9. - PubMed
Dorow 1984 {published data only}
    1. Dorow P, Tonnesmann U. Dose‐response relationship of the beta‐adrenoceptor antagonist bisoprolol in patients with coronary heart disease and chronic obstructive bronchitis. European Journal of Clinical Pharmacology 1984;27:135‐9. - PubMed
Dorow 1986c {published data only}
    1. Dorow P, Schiess W. Bopindolol, pindolol, and atenolol in patients with chronic obstructive lung disease. Klinische Wochenschrift 1986;64(8):366‐9. - PubMed
George 1983 {published data only}
    1. George RB, Manocha K, Burford JG, Conrad SA, Kinasewitz GT. Effects of labetalol in hypertensive patients with chronic obstructive pulmonary disease. Chest 1983;83(3):457‐60. - PubMed
Jabbour 2010 {published data only}
    1. Jabbour A, Macdonald PS, Keough AM, Kotlyar E, Mellenkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS. Differences between beta‐blockers in patients with chronic heart failure and chronic obstructive pulmonary disease. Journal of the American College of Cardiology 2010;44:1780‐1787. - PubMed
Johnsson 1976 {published data only}
    1. Johnsson G. Use of beta‐adrenergic blockers in combination with beta‐stimulators in patients with obstructive lung disease. Drugs 1976;11(Suppl 1):171‐7. - PubMed
Lois 1997 {published data only}
    1. Lois M, Honig E. Beta‐blockade post‐MI: safe for patients with asthma or COPD?. The Journal of Respiratory Diseases 1997;18(6):568‐91.
Lois 1999 {published data only}
    1. Lois M, Roman J, Honig E. Using beta‐blockers for CHF in patients with COPD. The Journal of Respiratory Diseases 1999;20(1):31‐43.
Meier 1966a {published data only}
    1. Meier VJ, Lydtin H, Zollner N. [On the effect of adrenergic beta‐receptor‐blocking agents on the ventilatory function in obstructive lung diseases]. Deutsche Medizinische Wochenschrift 1966;91(4):145‐7. - PubMed
Meier 1966b {published data only}
    1. Meier J, Lydtin H, Zollner N. The action of adrenergic beta‐receptor blockers on ventilatory functions in obstructive lung diseases. German Medical Monthly 1966;11(1):1‐3. - PubMed
Nordstrom 1975 {published data only}
    1. Nordstrom LA, MacDonals F, Gobel FL. Effect of propranolol on respiratory function and exercise tolerance in patients with chronic obstructive lung disease. Chest 1975;67(3):287‐92. - PubMed
Quan 1983 {published data only}
    1. Quan SF, Fenster PE, Hanson CD, Coaker LA, Basista MP. Suppression of atrial ectopy with intravenous metoprolol in chronic obstructive pulmonary disease patients. Journal of Clinical Pharmacology 1983;23(8‐9):341‐7. - PubMed
Ulmer 1976 {published data only}
    1. Ulmer I, Lanser K. Propranolol and Pindolol in chronic obstructive pulmonary disease [Propranolol und Pindolol bei chronisch‐obstruktiver Atemwegserkrankung.]. Deutsche Medizinische Wochenschrift 1976;101(48):1765‐8. - PubMed
van Herwaarden 1983 {published data only}
    1. Herwaarden CL. Beta‐adrenocepptor blockade and pulmonary function in patients suffering from chronic obstructive lung disease. Journal of Cardiovascular Pharmacology 1983;5(Suppl 1):S46‐50. - PubMed
Wettengel 1970 {published data only}
    1. Wettengel R, Fabel H. Effect of different beta‐receptor blocking agents on ventilation in obstructive respiratory tract disease. Comparative studies [Wirkung verschiedener beta‐Rezeptoren‐Blocker auf die Ventilation bei. Vergleichenden Untersuchungen]. Deutsch Medizinische Wochenschrift 1970;95(36):1816‐21. - PubMed

References to studies awaiting assessment

Mainguy 2010 {published data only}
    1. Mainguy V, Girard D, Saey D, Milot J, Maltais F, Provencher S. Effects of cardioselective beta‐blockers on dynamic hyperinflation and on exercise tolerance in moderate‐to‐severe copd [Abstract]. Canadian Respiratory Journal [Revue canadienne de pneumologie] 2010;8(2):e27.

Additional references

Abdulla 2006
    1. Abdulla J, Kober L, Christensen E, Torp‐Pedersen C. Effect of beta‐blocker therapy on functional status in patients with heart failure ‐ a meta‐analysis. European Journal of Heart Failure 2006;8(5):522‐31. - PubMed
Anderson 1979
    1. Anderson EG, Calcraft B, Jariwalla AG, Al‐Zaibak M. Persistent asthma after treatment with beta‐blocking agents. British Journal of Diseases of the Chest 1979;73(4):407‐8. - PubMed
ATS 1995
    1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. American Journal of Respiratory and Critical Care Medicine 1995;152(5 Pt 2):S77‐121. - PubMed
Au 2004
    1. Au DH, Bryson CL, Fan US, Udris EM, Curtis JR, McDonell MB, Fihn SD. Beta‐blockers as single‐agent therapy for hypertension and the risk fo mortality among patients with chronic obstructive pulmonary disease. American Journal of Medicine 2004;117:925‐931. - PubMed
Beattie 2008
    1. Beattie WS, Wijeysundera DN, Karkouti K, McCluskey S, Tait G. Does tight heart rate control improve beta‐blocker efficacy? An updated analysis of the noncardiac surgical randomized trials. Cardiovascular Anesthesiology 2008;106:1039‐1048. - PubMed
Belli 1995
    1. Belli G, Topol EJ. Adjunctive pharmacologic strategies for acute MI. Contemporary Internal Medicine 1995;7(8):51‐9. - PubMed
Beto 1992
    1. Beto JA, Bansal VK. Quality of life in treatment of hypertension: A meta‐analysis of clinical trials. American Journal of Hypertension 1992;5(3):125‐33. - PubMed
Bright 1992
    1. Bright J, Everitt DE. Beta‐blockers and depression: Evidence against an assoication. JAMA 1992;267(13):1783‐7. - PubMed
Chafin 1999
    1. Chafin CC, Soberman JE, Demirkan K, Self T. Beta‐blockers after myocardial infarction: Do benefits ever outweigh risks in asthma?. Cardiology 1999;92:99‐105. - PubMed
Chen 2001
    1. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of beta‐blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. Journal of the American College of Cardiology 2001;37:1950‐6. - PubMed
Craig 1996
    1. Craig T, Richerson HB, Moeckli J. Problem drugs for the patient with asthma. Comprehensive Therapy 1996;22(6):339‐44. - PubMed
DerSimonian 1986
    1. DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7:177‐88. - PubMed
Doughty 1997
    1. Doughty RN, Rodgers A, Sharpe N, MacMahon S. Effects of beta‐blocker therapy on mortality in patients with heart failure. European Heart Journal 1997;18(4):560‐5. - PubMed
Dransfield 2008
    1. Dransfield MT, Rowe SM, Johnson JE, Bailey WC, Gerald LB. Use of beta‐blockers and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax 2008;63:301‐305. - PubMed
Egred 2005
    1. Egred M, Shaw M, Mohammad B, Waitt P, Rodrigues E. Under‐use of beta‐blockers in patients with ischemic heart disease and comcomitant chronic obstructive pulmonary disease. QJM 2005;7:493‐397. - PubMed
Falliers 1985
    1. Falliers CJ, Vrchota J, Blasucci DJ, Maloy JW, Medakovic M. The effects of treatments with labetalol and hydrochlorothiazide on ventilatory function of asthmatic hypertensive patients with demonstrated bronchosensitivity to propranolol. Journal of Clinical Hypertension 1985;1(1):70‐9. - PubMed
Fitzgerald 1991
    1. Fitzgerald J. The applied pharmacology of beta‐adrenoceptor antagonist (beta‐blockers) in relation to clinical outcomes. Cardiovascular Drugs and Therapy 1991;5:561‐76. - PubMed
Formgren 1976
    1. Formgren H. The effect of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics. British Journal of Clinical Pharmacology 1976;3:1007‐14. - PMC - PubMed
Freemantle 1999
    1. Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999;318:1730‐7. - PMC - PubMed
Gottlieb 1998
    1. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta‐blockade on mortality among high‐risk and low‐risk patients after myocardial infarction. New England Journal of Medicine 1998;339(8):489‐97. - PubMed
Heidenreich 1999
    1. Heidenreich PA, McDonald KM, Hastie T, Fadel B, Lee BK, Hlatky MA. Meta‐analysis of trials comparing beta‐blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281(20):1927‐36. - PubMed
Heller 2000
    1. Heller DA, Ahern FM, Kozak M. Changes in rates of beta‐blocker use between 1994 and 1997 among elderly survivors of acute myocardial infarcion. American Heart Journal 2000;140:663‐71. - PubMed
Hulsmann 2001
    1. Hulsmann M, Sturm B, Pacher R, Berger R, Bojic A, Frey B, Stanek B. Long‐term effect of atenolol on ejection fraction, symptoms, and exercise variables in patients with advanced left ventricular dysfunction. Journal of Heart and Lung Transplantation 2001;20(11):1174‐80. - PubMed
Ionnidis 1999
    1. Ionnidis JP, Lau J. Pooling research results: benefits and limitations of meta‐analysis. The Joint Commission Journal on Quality Improvement 1999;25(9):462‐9. - PubMed
IPPSH 1985
    1. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randonized trial of treatment based on the beta‐blocker oxprenolo: The Internation Prospective Primary Prevention Study in Hypertension (IPPPSH). Journal of Hypertension 1985;3:379‐92. - PubMed
JNC 1997
    1. JNC VI. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Archives of Internal Medicine 1997;157:2413‐46. - PubMed
Jonas 1996
    1. Jonas M, Reicher‐Reiss H, Boyko V, Shotan A, Mandelzweig L, Goldbourt U, et al. Usefulness of beta‐blocker therapy in patients with non‐insulin‐dependent diabetes mellitus and coronary artery disease. American Journal of Cardiology 1996;77:1273‐7. - PubMed
Jones 1980
    1. Jones M, John R, Jones G. The effect of oxprenolol, acebutolol and propranolol on thyroid hormones in hyperthyroid subjects. Clinical Endocrinology 1980;13:343‐7. - PubMed
Kendall 1997
    1. Kendall MJ. Clinical relevance of pharmacokinetic differences between beta blockers. American Journal of Cardiology 1997;80(9B):15J‐9J. - PubMed
Kennedy 1995
    1. Kennedy HL, Rosenson RS. Physician use of beta‐adrenergic blocking therapy: A changing perspective. Journal of the American College of Cardiology 1995;26(2):547‐52. - PubMed
Kjekshus 1990
    1. Kjekshus J, Gilpin E, Cali G, Blackey AR, Henning H, Ross J. Diabetic patients and beta‐blockers after acute myocardial infarction. European Heart Journal 1990;11:43‐50. - PubMed
Klein 1994
    1. Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Annals of Internal Medicine 1994;121(3):281‐8. - PubMed
Koch‐Weser 1984
    1. Koch‐Weser J. Beta‐adrenergic blockade for survivors of acute myocardial infarction. New England Journal of Medicine 1984;310:830‐7. - PubMed
Krauss 1984
    1. Krauss S, Spitz E, Krauss A, Grizotzki B, Clement S. Treatment of hypertension in mild asthmatic patients with atenolol. Angiology 1984;35(12):773‐8. - PubMed
Krumholz 1998
    1. Krumholz HM, Radford MJ, Wang Y, Chen J, Heiat A, Marciniak TA. National use and effectiveness of beta‐blcokers for the treatment of elderly patients after acute myocardial infarction. JAMA 1998;280(7):623‐9. - PubMed
Krumholz 1999
    1. Krumholz HM, Radford MJ, Wang Y, Chen J, Marciniak TA. Early beta‐blocker therapy for acute myocardial infarction in elderly patients. Annals of Internal Medicine 1999;131(9):648‐54. - PubMed
Lechat 1998
    1. Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel J. Clinical effects of beta‐adrenergic blockade in chronic heart failure: A meta‐analysis of placebo‐controlled, randomized trials. Circulation 1998;98:1184‐91. - PubMed
Mangano 1996
    1. Mangano DT, Layug EL, Wallace A, Tateo I. Atenolol reduced mortality and cardiovascular events after noncardiac surgery. New England Journal of Medicine 1996;335:1713‐20. - PubMed
Mantel 1959
    1. Mantel N, Haenszel WH. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute 1959;22:719‐48. - PubMed
McGory 2005
    1. McGory ML, Maggard MA, Ko CY. A meta‐analysis of perioperative beta blockade: What is the actual risk reduction?. Surgery 2005;138:171‐179. - PubMed
McNeill 1964
    1. McNeill RS. Effect of a beta‐adrenergic‐blocking agent, propranolol, on asthmatics. Lancet 1964;2:1101‐2. - PubMed
Mooss 1994
    1. Mooss AN, Hillerman DE, Syed MM, Hunter CB. Safety of esmolol in patients with acute myocardial infaction treated with thrombolytic therapy who had relative contraindications to beta‐blocker therapy. Annals of Pharmacotherapy 1994;28(6):701‐3. - PubMed
O'Malley 1991
    1. O'Malley K, Cox JP, O'Brien E. Choice of drug treatment for elderly hypertensive patients. The American Journal of Medicine 1991;90(Suppl 3A):27S‐33S. - PubMed
Opie 1990
    1. Opie LH. Required beta blocker profile in the elderly. Cardiovascular Drugs and Therapy 1990;4:1273‐80. - PubMed
Poulsen 2000
    1. Poulsen SH, Jensen SE, Egstrup K. Improvement in exercise capacity and left ventricular diastolic function with metoprolol XL after acute myocardial infarction. American Heart Journal 2000;140(1):E6‐11. - PubMed
Radack 1991
    1. Radack K, Deck C. Beta‐adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: a meta‐analysis of randomized controlled trials. Archives of Internal Medicine 1991;151:1769‐76. - PubMed
Raine 1981
    1. Raine JM, Palazzo MG, Kerr JH, Sleight P. Near fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane. British Medical Journal 1981;282:548‐9. - PMC - PubMed
Rosenson 1993
    1. Rosenson RS. The truth about beta‐blocker adverse effects ‐ depression, claudication, and lipids. Journal of Ambulatory Monitoring 1993;6(2):163‐71.
Rutten 2010
    1. Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. Beta‐blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Archives of Internal Medicine 2010;170:880‐887. - PubMed
Salpeter 2002
    1. Salpeter S, Ormiston T, Salpeter E, Wood‐Baker R. Cardioselective beta‐blockers for reversible airway disease (Cochrane Review). Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD002992] - DOI - PubMed
Sial 1994
    1. Sial SH, Malone M, Freeman JL, Battiola R, Nachodsky J, Goodwin JS. Beta blocker use in the treatment of community hospital patients discharged after myocardial infarction. Journal of General Internal Medicine 1994;9:599‐605. - PubMed
Soumerai 1997
    1. Soumerai SB, McLaughlin TJ, Spiegelman D, Hertzmark E, Thibault G, Goldman L. Adverse outcomes of underuse of beta‐blockers in elderly survivors of acute myocardial infarction. JAMA 1997;277(2):115‐21. - PubMed
Steinbeck 1992
    1. Steinbeck G, Andresen D, Bach P, Haberi R, Oeff M, Hoffmann E, et al. A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta‐blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. New England Journal of Medicine 1992;327(14):987‐92. - PubMed
Tattersfield 1986
    1. Tattersfield AE. Beta adrenergic antagonists and respiratory disease. Journal of Cardiovascular Pharmacology 1986;8(Suppl 4):S35‐S9. - PubMed
Tattersfield 1990
    1. Tattersfield AE. Respiratory function in the elderly and the effects of beta blockade. Cardiovascular Drugs and Therapy 1990;4:1229‐32. - PubMed
Van Gestel 2008
    1. Gestel YRBM, Hoeks SE, Sin DD, Welten GMJM, Schouten O, Witteveen HT, Simsek C, Stam H, Mertens FW, Bax JJ, Domburg RJ, Poldermans D. Impact of cardioselective beta‐blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. American Journal of Respiratory and Critical Care Medicine 2008;178:695‐700. - PubMed
Viskin 1996
    1. Viskin S, Barron HV. Beta blockers prevent cardiac death following a myocardial infarction: so why are so many infarct survivors discharged without beta blockers?. American Journal of Cardiology 1996;78:821‐2. - PubMed
Wadworth 1991
    1. Wadworth AN, Murdoch D, Brogden RN. Atenolol: A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders. Drugs 1991;42(3):468‐510. - PubMed
Wang 1998
    1. Wang TJ, Stafford RS. National patterns and predictors of beta‐blocker use in patients with coronary artery disease. Archives of Internal Medicine 1998;158:1901‐06. - PubMed
Wellstein 1987
    1. Wellstein A, Palm D, Belz G, Butzer R, Polsak R, Pett B. Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta‐adrenoceptor occupancy. European Heart Journal 1987;8(Suppl M):3‐8. - PubMed
Wicklmayr 1990
    1. Wicklmayr M, Rett K, Dietze G, Mehnert H. Effects of beta‐blocking agents on insulin secretion and glucose disposal. Hormone and Metabolic Research 1990;22(5):29‐33. - PubMed
Yusuf 1985
    1. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta‐blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Diseases 1985;27(5):335‐71. - PubMed
Zaid 1966
    1. Zaid G, Beall GN. Bronchial response to beta‐adrenergic blockade. New England Jpurnal of Medicine 1966;275:580‐4. - PubMed

MeSH terms

Substances